Keyphrases
Indinavir
55%
Pharmacist
45%
Pharmacokinetics
41%
Normal Volunteers
41%
Steady State
37%
Doxorubicin
37%
Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF)
37%
Pharmacist Attitudes
37%
COVID-19
37%
Self-administration
37%
Clarithromycin
37%
Recombinant Human
37%
Yohimbine
37%
New Jersey
32%
Cmax
29%
Dose Effect
28%
Pediatric
27%
Student Perceptions
26%
Cocaine
24%
Concomitant Administration
23%
Oral Administration
23%
Team-based
23%
Healthy Volunteers
22%
Modal
22%
Neonatal Intensive Care Unit
22%
Pharmacokinetic Effects
22%
Indinavir Sulphate
22%
Pharmacy Students
21%
Placebo
21%
Pediatric COVID-19
18%
Myelotoxicity
18%
Synthetase
18%
Induced Hepatotoxicity
18%
Epigallocatechin-3-gallate
18%
Emerging Approaches
18%
Liver Injury
18%
Donepezil
18%
Peripheral Blood Progenitor Cells
18%
Emergency Medicine Pharmacist
18%
Metabolism
18%
Cytokine Release Syndrome
18%
Filtration
18%
Repeated Dosing
18%
Hepatotoxicity Mechanisms
18%
Pharmacist Knowledge
18%
Withdrawal Management
18%
Cardiovascular Effects
18%
Trough Serum Concentration
18%
Rh Blood Type
18%
Interleukin-3
18%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Normal Human
67%
Indinavir
55%
Clarithromycin
37%
Doxorubicin
37%
Recombinant Granulocyte Colony Stimulating Factor
37%
Yohimbine
37%
Diseases
30%
Elimination
25%
Phenobarbital
24%
Syndrome
21%
Adverse Event
20%
Prevalence
19%
Placebo
18%
Proteinase Inhibitor
18%
Bone Marrow Toxicity
18%
Dietary Fat
18%
Synthetase
18%
Acetylcholine
18%
Donepezil
18%
Raynaud Phenomenon
18%
Coronavirinae
18%
Pharmacotherapy
18%
Macrolide
18%
Cytokine Release Syndrome
18%
Leporidae
18%
Dopamine Receptor D2
18%
Drug Formulation
18%
Enzyme Induction
18%
Epigallocatechin Gallate
18%
Interleukin 10
18%
Community Pharmacy
18%
Chimeric Antigen Receptor
18%
Interleukin 3
18%
Cancer Chemotherapy
18%
Observational Study
18%
Drug Utilization
18%
Systemic Administration
18%
Dopamine 1 Receptor
18%
Cotrimoxazole
18%
Cholinesterase Inhibitor
18%
Hospital Pharmacy
18%
Hepatotoxicity
18%
Cross Sectional Study
18%
Human Immunodeficiency Virus Proteinase
18%
Liver Injury
18%
Alphan3 Interferon
18%
Liver Enzyme
18%
Idiopathic Thrombocytopenic Purpura
18%
Injury
18%